We are live on ! Find out more
SIOX

Sio Gene Therapies Inc. Common Stock
SIOX

Delisted

SIOX was delisted on the 22nd of March, 2023.

Back to rankings

48 hedge funds and large institutions have $27.6M invested in Sio Gene Therapies Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more call options, than puts

Call options by funds: $205K | Put options by funds: $126K

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

14% less funds holding

Funds holding: 56 → 48 (-8)

31% less capital invested

Capital invested by funds: $39.9M → $27.6M (-$12.3M)

50% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 14

Holders
48
Holders Change
-8
Holders Change %
-14.29%
% of All Funds
0.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
15
Reduced
13
Closed
14
Calls
$205K
Puts
$126K
Net Calls
+$79K
Net Calls Change
-$313K

Top Buyers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
+$754K
2
BlackRock
BlackRock
New York
+$689K
3
Ameriprise
Ameriprise
Minnesota
+$652K
4
PM
Prosight Management
Texas
+$548K
5
CC
Clearline Capital
New York
+$388K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$2.07M
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$935K
3
GCP
GSA Capital Partners
United Kingdom
-$453K
4
Renaissance Technologies
Renaissance Technologies
New York
-$282K
5
Two Sigma Investments
Two Sigma Investments
New York
-$253K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Suvretta Capital Management
New York
$7.63M +$754K +425,000 +8%
RCMNY
2
Rubric Capital Management (New York)
New York
$3.87M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.77M +$172K +96,664 +5%
PFM
4
Privium Fund Management
Netherlands
$2.37M +$3.21M +1,806,542 New
Hudson Bay Capital Management
5
Hudson Bay Capital Management
Connecticut
$2.32M +$346K +195,000 +12%
CIA
6
Cladis Investment Advisory
Montana
$1.55M +$2.14M +1,204,000 New
PM
7
Prosight Management
Texas
$1.03M +$548K +308,972 +63%
Renaissance Technologies
8
Renaissance Technologies
New York
$843K -$282K -158,903 -20%
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$713K +$286K +161,102 +41%
BlackRock
10
BlackRock
New York
$685K +$689K +388,383 +273%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$556K +$66.4K +37,404 +9%
Ameriprise
12
Ameriprise
Minnesota
$494K +$652K +367,404 +2,516%
BCM
13
Bridgeway Capital Management
Texas
$445K -$122K -69,000 -17%
CC
14
Clearline Capital
New York
$282K +$388K +218,506 New
ACM
15
ACT Capital Management
Pennsylvania
$239K – – –
GCP
16
GSA Capital Partners
United Kingdom
$215K -$453K -255,342 -60%
State Street
17
State Street
Massachusetts
$203K +$83.8K +47,200 +43%
Millennium Management
18
Millennium Management
New York
$190K -$64.7K -36,475 -20%
Citadel Advisors
19
Citadel Advisors
Florida
$174K +$136K +76,470 +131%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$142K +$146K +82,264 +298%
Northern Trust
21
Northern Trust
Illinois
$112K – – –
Franklin Resources
22
Franklin Resources
California
$106K -$671 -378 -0.5%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$92K -$31.2K -17,563 -20%
Macquarie Group
24
Macquarie Group
Australia
$83K – – –
AC
25
Apogem Capital
New York
$78K +$36.9K +20,803 +53%
1
2 3

SIOX Hedge Fund Activity: Q4 2021 in Review

48 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q4 2021, worth a combined $27.6M — down 31% from $39.9M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of SIOX and 7 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 15 added.

The largest buyer was Suvretta Capital Management, adding an estimated $754K. The largest seller was Opaleye Management, exiting entirely with an estimated $2.07M sold.

  • 48 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q4 2021, down from 56 in Q3 2021.
  • Funds reported $27.6M of Sio Gene Therapies Inc. Common Stock stock for Q4 2021, down 31% quarter-over-quarter.
  • 7 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q4 2021 and 14 closed out, a net change of -7 holders.
  • The largest Sio Gene Therapies Inc. Common Stock buyer in Q4 2021 was Suvretta Capital Management, an estimated $754K added.
  • The largest Sio Gene Therapies Inc. Common Stock seller in Q4 2021 was Opaleye Management, an estimated $2.07M sold.

Based on aggregated 13F filings for Q4 2021.